Zafgen stock tumbles once hedge fund reveals short position

Zafgen's stock tumbled the maximum amount as eleven.5 p.c on weekday once hedge fund Kerrisdale Capital same it's a brief wager the biopharmaceutical company's stock, tilt that U.S. regulators won't approve the sale of its fat drug.

"Zafgen's deadly fat drug (beloranib) has no affordable likelihood of federal agency approval," the hedge fund wrote in associate 11-page report issued on weekday, adding that Zafgen's stock is price solely $3 a share. it absolutely was down half-dozen.7 p.c to $8.25 in late morning commercialism on weekday.

Kerrisdale, that manages regarding $400 million, has created a splash with bets against big-name firms and is one among solely alittle variety of hedge funds to in public disclose its short positions, within which the stock is borrowed and sold  with the expectation it'll fall and be bought back at a cheaper price.

Zafgen's stock has been volatile within the last 2 months amid news regarding beloranib. Last week it rallied seventy nine p.c once some investment analysts issued new "buy" ratings once the corporate discharged results from late-stage trials that showed some promise in reducing weight in patients littered with Prader-Willi syndrome.

Some investors were optimistic those results would possibly prompt the Food and Drug Administration to get rid of the clinical hold on the treatment, that was placed on last year once 2 patients died. within the last fifty two weeks, Zafgen's stock has tumbled seventy eight.52 percent.

In its report titled "FDA Approval for a Deadly Drug? probability," Kerrisdale wrote "Nothing meaty has changed: beloranib is very dangerous however solely with modesty effective."

"The federal agency won't approve beloranib, and Zafgen is price nothing quite the current worth of its future money balance, that we tend to estimate is sixty five p.c below this value," the hedge fund another.

Laura Perry, a Zafgen voice, same the corporate doesn't investigate commercialism activity.

Kerrisdale, pass Sahm Adrangi, is uncommon within the close hedge fund trade as a result of it makes its short positions public, one thing most will not do for worry of losing access to a company's management. It proclaimed variety of public shorts in 2015, together with Allied Minds and state Nordic.

The fund was up eighteen p.c through the tip of Nov, performing arts higher|much better} than several of its larger and better legendary rivals during a year the common hedge fund was off roughly one p.c.